CPD and Education library

Study and gain CPD points through OT’s online CPD exams, and access archived CPD and CET articles, Practice team resources and Skills guides in our Education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Allergan presents data on treatments for AMD and glaucoma

The company highlighted a potential “first-in-class” treatment for reducing intraocular pressure

open eye
Pharmaceutical company Allergan presented data on treatments for age-related macular degeneration (AMD) and glaucoma at the American Academy of Ophthalmology (AAO) meeting in San Francisco, US (12–15 October).

Allergan presented two-year data from clinical studies of Abicipar in patients with neovascular AMD, as well as presenting data on Bimatoprost Sustained Release.

It highlighted that Bimatoprost Sustained Release has the potential to be a “first-in-class” biodegradable implant for the reduction of intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Senior vice president and head of global clinical development at Allergan, Dr Yehia Hashad, said: “The data presented at AAO for our late stage, investigational assets, Abicipar and Bimatoprost Sustained-Release, showcase our continued commitment to innovation in ophthalmology. We’re excited to share data that may redefine treatment approaches in neovascular age-related macular degeneration and glaucoma, and may improve upon the current state of patient care.”

Image credit: Pixabay/Tobias Dahlberg